Invitae (NYSE:NVTA) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Invitae (NYSE:NVTA) in a report released on Wednesday. The firm set a “hold” rating on the medical research company’s stock.

Invitae Stock Performance

NVTA opened at $0.00 on Wednesday. The firm has a market cap of $267,010.00, a price-to-earnings ratio of 0.00 and a beta of 1.59. Invitae has a 12 month low of $0.02 and a 12 month high of $0.02. The stock has a fifty day moving average price of $0.01 and a 200-day moving average price of $0.33.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Invitae by 4.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,652,650 shares of the medical research company’s stock worth $1,000,000 after purchasing an additional 64,228 shares during the last quarter. Barclays PLC grew its stake in Invitae by 698.2% during the 3rd quarter. Barclays PLC now owns 905,531 shares of the medical research company’s stock worth $548,000 after buying an additional 792,091 shares during the last quarter. Vestmark Advisory Solutions Inc. acquired a new position in Invitae during the 4th quarter valued at about $526,000. Longitude Cayman Ltd. raised its stake in Invitae by 29.3% in the third quarter. Longitude Cayman Ltd. now owns 776,000 shares of the medical research company’s stock valued at $470,000 after buying an additional 176,000 shares during the last quarter. Finally, HighTower Advisors LLC boosted its holdings in Invitae by 14.1% in the third quarter. HighTower Advisors LLC now owns 600,354 shares of the medical research company’s stock worth $339,000 after acquiring an additional 74,405 shares in the last quarter. Institutional investors own 61.28% of the company’s stock.

Invitae Company Profile

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.